Filing summary: quarter ended June 30, 2023
Entity mismatch: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-Q, not a filing identified as Gyre Therapeutics, Inc. Verify the issuer before relying on this summary.
Business context and reporting period
Catalyst had ceased its prior research and development activities by 2022 and sold its complement portfolio to Vertex and legacy rare bleeding disorder programs to GC Biopharma (GCBP). It acquired rights outside China to F351, a clinical-stage candidate for liver fibrosis, and was pursuing a transaction to acquire an indirect controlling interest in China-based Beijing Continent Pharmaceutical (BC). The report covers the three and six months ended June 30, 2023; the statements are unaudited.
Financial performance and position
- Revenue: No collaboration revenue in Q2 or the first half of 2023. First-half 2022 collaboration revenue was $0.8 million; the company reported no drug-product sales.
- Profit and expenses: Q2 2023 net loss was $2.5 million, versus net income of $51.6 million in Q2 2022. First-half net loss was $2.2 million, versus net income of $37.1 million in first-half 2022. 2022 results included a $57.2 million net gain on asset disposals; first-half 2023 included a $4.7 million gain on the GCBP sale. First-half 2023 R&D expense was $0.9 million and G&A was $6.2 million.
- Cash flow: First-half operating cash use was $8.7 million, investing cash provided was $5.2 million, and financing cash used was $11.3 million, primarily reflecting dividends and CVR distributions. Cash declined $14.7 million over the period.
- Liquidity and balance sheet: Cash and cash equivalents were $6.9 million at June 30, down from $21.7 million at December 31, 2022. Total assets were $12.4 million and total liabilities were $7.4 million; there was no reported debt balance. The balance sheet included a $4.6 million long-term GCBP receivable, matched by a $4.6 million noncurrent CVR derivative liability.
- Margins: The filing does not provide a meaningful product gross margin; the company had no product sales and no 2023 collaboration revenue.
Material changes versus comparable periods
- Compared with first-half 2022, R&D expense fell 92% and G&A expense fell 30%, reflecting the cessation of legacy programs and reduced operations. The 2022 comparison also included the large Vertex disposal gain, making reported net income non-recurring and not directly indicative of ongoing performance.
- Cash fell substantially during the first half of 2023, including after a $7.6 million special dividend and distributions to CVR holders. The $5.0 million GCBP holdback is expected in 2025, subject to indemnification conditions, and net proceeds are payable to CVR holders.
- Common shares outstanding were 37,974,892 at June 30, 2023. Separately, 12,340 shares of convertible preferred stock could convert into 123.4 million common shares if approved, subject to applicable limitations.
Outlook, risks, and contingencies
- Going concern and redemption risk: Management stated there was substantial doubt about the company’s ability to continue as a going concern for at least 12 months, principally because stockholder approval was required to convert the preferred stock. If approval was not obtained by September 30, 2023, holders could seek cash redemption. Using the August 7 share price, the filing estimated the potential payment at approximately $43.2 million, far exceeding available liquidity. Management expected stockholders to approve conversion, but the vote was outside its control.
- Proposed business combination: The planned BC transaction required stockholder approval and other closing conditions. If approved, Catalyst could issue up to 1,110,776,224 common shares for the indirect controlling interest. Certain termination circumstances could trigger a $2.0 million fee, with expense reimbursement also potentially due up to $2.0 million.
- Operating outlook: Management said cash could support operating expenses for at least 12 months if the conversion proposal passed, but emphasized that estimates rely on assumptions and cash needs could rise. GNI was to fund certain F351 development costs until the business combination closed; Catalyst expected no material R&D expenses until then.
- Listing risk: Nasdaq had identified deficiencies in the minimum bid price and stockholders’ equity requirements. The company had until October 30, 2023 to regain compliance with initial listing requirements; delisting could harm liquidity, financing access, and the proposed transaction.
- Other items: The company reported no material legal proceedings. Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm that this Catalyst Biosciences filing—not a Gyre Therapeutics filing—is the intended source.
- Check the outcome of the stockholder votes on preferred-stock conversion and the proposed business combination, including the resulting dilution and any redemption obligations.
- Verify subsequent cash balances, operating cash use, and the status and timing of the GCBP holdback and CVR distributions.
- Check whether Nasdaq listing compliance was restored and whether the proposed business combination closed.